Clinical & experimental expertise in speech testing
Redenlab’s approach to speech testing and analysis is sensitive to disease progression, treatment response and the ephemeral effects of conditions known to change central nervous system function. We have worked with hereditary ataxias, Huntington’s and Parkinson’s disease, fronto-temporal dementia and primary progressive aphasia, multiple sclerosis, fatigue, stimulant and sedative use and depression. The reasoning and evidence for the validity, reliability and sensitivity of speech to central nervous system integrity is detailed in these publications.
Cerebellar disorders (ataxia)
Redenlab scientists are world leaders in the measurement of speech and swallowing in ataxia. Speech intelligibility, quality, control and perception typically declines over time in hereditary ataxia. We have systematically documented the speech phenotype in these disorders with evidence of subtle changes in speech over time and treatment response in the most common genetically inherited ataxia, Friedreich ataxia and other rare ataxias.
The psychomotor and affective changes resulting from major depressive disorder or other affective disorders means speech is a viable marker of disease progression and treatment response. Redenlab scientists have authored landmark speech-depression studies with access to large speech databases for evaluating novel algorithms and stimuli stability in trials of treatment efficacy and disease trajectory.
Huntington's & parkinson's disease
Movement disorders like Huntington's disease (HD), Parkinson's disease (PD) or diseases that lead to changes in motor function result in changes to speech. Redenlab have expertise and data on these disorders, including identification of subtle alterations in performance during the prodromal (pre-symptomatic) stages and response to treatment.
Partnering with leading industry and university researchers through public-private initiatives, Redenlab are developing novel algorithms and hardware platforms for detecting alertness in fitness-for-duty assays in the clinical workforce, transport and mining industries.
Monitoring behavioral change in Alzheimer's disease and the fronto-temporal-lobar dementias (FTLD) is complex. Speech and language function can be compromised in these disorders. Redenlab are experts in speech analysis in FTLD with capacity for informing protocol design and patient management in all dementias.
developmental & genetic communication disorders
Redenlab have sophisticated knowledge on speech and language assessment, disease trajectory and deep phenotyping in a range of developmental and child onset genetic disorders including Dravet syndrome, FOXP2, childhood posterior fossa tumour, 16p11.2, focal epilepsies, Kabuki syndrome, Koolen-de Vries syndrome, GRIN2A, cerebral palsy, autism, speech sound disorder, preterm and traumatic brain injury. Evidence of our expertise can be found in these publications.